Last $9.39 USD
Change Today +0.10 / 1.08%
Volume 95.4K
HRTX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

heron therapeutics inc (HRTX) Snapshot

Open
$9.33
Previous Close
$9.29
Day High
$9.43
Day Low
$9.16
52 Week High
03/20/14 - $15.82
52 Week Low
09/16/13 - $6.40
Market Cap
271.5M
Average Volume 10 Days
105.6K
EPS TTM
$-1.60
Shares Outstanding
28.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HERON THERAPEUTICS INC (HRTX)

Related News

No related news articles were found.

heron therapeutics inc (HRTX) Related Businessweek News

No Related Businessweek News Found

heron therapeutics inc (HRTX) Details

Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company’s drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

47 Employees
Last Reported Date: 03/7/14
Founded in 1983

heron therapeutics inc (HRTX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $349.3K
President, Director and Member of Audit and F...
Total Annual Compensation: $453.8K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $52.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $361.5K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $312.0K
Compensation as of Fiscal Year 2013.

heron therapeutics inc (HRTX) Key Developments

Heron Therapeutics Names Esme C. Smith as VP, General Counsel and Secretary

Heron Therapeutics annunced that Esme C. Smith will join the Company as Vice President, General Counsel and Secretary. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer. Prior to joining full-time, Smith advised the Company on legal matters. Previously, she served as Vice President, Deputy General Counsel and Assistant Secretary at Dendreon Corp., from July 2009 through March 2012.

Heron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and Secretary

Heron Therapeutics, Inc. announced that Esmé C. Smith will join the company as Vice President, General Counsel and Secretary, effective August 25, 2014. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer. Prior to joining full-time, Ms. Smith advised the company on legal matters. Previously, she served as Vice President, Deputy General Counsel and Assistant Secretary at Dendreon Corporation, from July 2009 through March 2012.

Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Heron Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's loss from operations was $18,791,000, compared to $15,209,000 for the last year. Net loss was $19,011,000 or $0.78 per basic and diluted share, compared to $15,413,000 or $1.01 per basic and diluted share for the last year. The increase in net loss was primarily due to the initiation of a Phase 3 label expansion study of SUSTOL in the first quarter of 2014 and expenses related to new product development, including new program targeting the relief of post-surgical pain, which was initiated in November 2013. For the six months, the company's loss from operations was $36,113,000, compared to $27,962,000 for the last year. Net loss was $36,549,000 or $1.52 per basic and diluted share, compared to $28,367,000 or $1.86 per basic and diluted share for the last year. The decrease in net loss per share for the three and six months ended June 30, 2014 compared to the same periods in 2013 was mainly due to the increase in shares outstanding in 2014 as a result of November 2013 and June 2014 common stock offerings, partially offset by the increase in net loss.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HRTX:US $9.39 USD +0.10

HRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.73 USD +0.25
Durect Corp $1.58 USD 0.00
Johnson & Johnson $103.73 USD +0.78
Pacira Pharmaceuticals Inc/DE $108.26 USD +0.47
Sanofi €83.50 EUR +1.03
View Industry Companies
 

Industry Analysis

HRTX

Industry Average

Valuation HRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HERON THERAPEUTICS INC, please visit www.appharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.